Glenmark Q1 FY27 Results: PAT rises to ₹4,828m

Results announced for quarter ended June 30, 2026

Glenmark Pharmaceuticals Limited disclosed its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company said the Board of Directors approved the financial statements at its meeting held on July 31, 2026. The set of results was accompanied by a Limited Review Report from statutory auditors. Glenmark also noted that the numbers were reviewed by the Audit Committee before being placed before the board. The update matters for investors because it provides the first official view of FY27 performance and the trajectory of margins across key markets. It also includes key corporate actions that affect shareholder entitlements.

Board actions: approval, review, and dividend record date

Along with the financial results, Glenmark’s board approved related compliance items required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also communicated a record date of August 31, 2026 to determine dividend entitlement for the financial year ended March 31, 2026. A record date is used to identify shareholders eligible to receive a declared dividend. The company’s communication ties this corporate action to the FY26 dividend, even as it reported Q1 FY27 financial performance. Glenmark also referenced that the results have undergone a limited review by statutory auditors, a standard procedure for quarterly unaudited results.

Standalone performance: income, profit, and EPS

On a standalone basis for the quarter ended June 30, 2026, Glenmark reported total income of ₹25,504.04 million. Profit after tax (PAT) for the period stood at ₹7,356.37 million. Total comprehensive income attributable to owners of the company was reported at ₹7,362.43 million. The company reported earnings per share (EPS) of ₹26.07 on both a basic and diluted basis for the quarter. These figures reflect the standalone financials of the parent entity, distinct from the consolidated numbers that include subsidiaries and other entities.

Consolidated performance: total income and profitability

For the same quarter on a consolidated basis, Glenmark reported total income of ₹40,842.47 million. Consolidated PAT was ₹4,828.28 million, while total comprehensive income attributable to owners of the company was ₹5,233.66 million. The company reported consolidated diluted EPS of ₹17.11. In a separate financial snapshot shared by the company, consolidated revenue was reported at ₹40,185 million, representing a 23.1% year-on-year increase from ₹32,644 million in the corresponding quarter last year. The company also reported PAT at ₹4,828 million in that snapshot, consistent with the consolidated PAT figure above when rounded.

Operating performance: EBITDA growth and margins

Glenmark reported EBITDA of ₹8,048 million for the quarter, up 38.6% year-on-year. The company stated that this translated into an EBITDA margin of 20.03%. PAT margin for the quarter was reported at 11.8%. Another market report summarised the operating momentum by stating EBITDA rose to ₹8,050 million from ₹5,810 million a year earlier, and that the margin improved to 20% from 17.8%. While the revenue line and profitability improved year-on-year, the company also reported higher expenses for the quarter in regulatory disclosures. Total expenses were ₹34,408.6 million compared with ₹28,720.7 million in the year-ago quarter.

Regional mix: India, North America, and Europe

The company indicated that growth was broad-based across key markets. India formulation revenue increased 15.5% year-on-year to ₹14,321 million. In another filing-based disclosure, North America revenue was reported at ₹10,974 million versus ₹7,780 million a year ago. Europe revenue was reported at ₹7,472 million compared with ₹6,678 million in the corresponding period last year. These region-wise numbers provide context on where growth was strongest during the quarter, alongside the consolidated improvement in margins.

Year-ago base and exceptional items

Glenmark’s filings highlighted a low base effect in the year-ago quarter. Consolidated PAT in the corresponding quarter last fiscal was reported at ₹469.7 million. The company also stated that the year-ago quarter included an exceptional item outgo of ₹3,232.3 million. In the June 2026 quarter, consolidated profit before tax (PBT) was reported at ₹6,430 million compared with ₹4,200 million in the prior year’s corresponding quarter. These disclosures help explain the scale of the year-on-year change in bottom line numbers reported for Q1 FY27.

Market reaction and investor datapoints

Following the results, Glenmark Pharmaceuticals shares ended at ₹2,238.50 on the BSE, up ₹47.45 or 2.17% for the day, as per the market update carried with the earnings coverage. Another market snapshot referenced a current market price (CMP) of ₹2,192.0 in its quick details section. Glenmark also scheduled an earnings call for August 3, 2026 from 8:30 am to 9:30 am IST, with dial-in access across multiple geographies including India, the USA, the UK, Singapore, and Hong Kong.

Key numbers table (all amounts in ₹ million)

Timeline and upcoming dates

Why the update matters

The quarter’s disclosures combine statutory reporting with market-facing operating highlights such as revenue growth, EBITDA expansion, and margin improvement. Investors typically track whether profit growth is supported by operating performance, and the reported increase in EBITDA alongside a higher EBITDA margin provides a clear datapoint for the quarter. At the same time, the company’s filing-based details on expenses show that cost levels rose year-on-year even as profitability improved. The record date announcement is a separate but important shareholder event because it determines eligibility for the FY26 dividend.

Conclusion

Glenmark’s Q1 FY27 update reported consolidated total income of ₹40,842.47 million and consolidated PAT of ₹4,828.28 million, alongside EBITDA of ₹8,048 million and an EBITDA margin of 20.03%. The board approved the unaudited results on July 31, 2026, and fixed August 31, 2026 as the record date for FY26 dividend entitlement. The next near-term event flagged by the company is the earnings call scheduled for August 3, 2026.